e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Prognostic factors in lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis
C. Mascaux, B. Martin, M. Paesmans, T. Berghmans, A. Haller, A. P. Meert, M. Dusart, P. Lothaire, J. J. Lafitte, J. P. Sculier (Brussels, Belgium; Lille, France)
Source:
Annual Congress 2005 - Prognostic factors in lung cancer
Session:
Prognostic factors in lung cancer
Session type:
Oral Presentation
Number:
3162
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Mascaux, B. Martin, M. Paesmans, T. Berghmans, A. Haller, A. P. Meert, M. Dusart, P. Lothaire, J. J. Lafitte, J. P. Sculier (Brussels, Belgium; Lille, France). COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis. Eur Respir J 2005; 26: Suppl. 49, 3162
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
A novel biologic classification of non-small cell lung cancer
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Year: 2005
Procalitonin: A prognosis factor in lung cancer and a marker for small-cell lung cancer
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Lung cancer
Source: Respipedia Article
Year: 2018
A non-small cell lung cancer modelling by endogenous κ-ras manipulation
Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection
Year: 2005
Trail receptors as prognostic factors in non-small cell lung cancer
Source: Annual Congress 2007 - Biology in thoracic oncology
Year: 2007
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Source: Eur Respir Rev 2011; 20: 45-52
Year: 2011
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
Source: Eur Respir J 2001; 18: 705-719
Year: 2001
Should there be a specific management for large cell neuroendocrine carcinoma?
Source: Annual Congress 2005 - Neuroendocrine tumours of the lung
Year: 2005
Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
Evaluation of the role of EGFR as prognostic factor in stage III non-small cell lung cancer (NSCLC): a retrospective analysis
Source: Eur Respir J 2004; 24: Suppl. 48, 478s
Year: 2004
Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
Source: Eur Respir J 2012; 39: 1437-1442
Year: 2012
PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: A 5-year-follow-up study
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011
Age and stage at presentation in lung cancer
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications
Source: Eur Respir J 2009; 33: 127-133
Year: 2009
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma
Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma
Year: 2006
Effects of prognostic factors on survival of the patients of non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 326s
Year: 2005
Staging of lung cancer
Source: Eur Respir Mon; 2009: 44: 150–168
Year: 2009
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept